Evidence map›Paper›PMID 32905447›Full record

ArticleJournal of cancer science and clinical therapeutics2020

Pharmacokinetics of Panaxynol in Mice.

Hossam Tashkandi, Anusha Chaparala, Sean Peng, Mitzi Nagarkatti, Prakash Nagarkatti, Alexander A Chumanevich, Lorne J Hofseth

Open access · diamondAbstract read
In one paragraph

Article in Journal of cancer science and clinical therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hossam TashkandiDrug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Anusha ChaparalaOB/GYN, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Sean PengTouchstone Biosciences, Plymouth Meeting, PA, USA.
Mitzi NagarkattiPathology, Microbiology, and Immunology, School of Medicine, University of South Carolina, Columbia, SC 29208, USA.
Prakash NagarkattiPathology, Microbiology, and Immunology, School of Medicine, University of South Carolina, Columbia, SC 29208, USA.
Alexander A ChumanevichDrug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Lorne J HofsethDrug Discovery and Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA.
University of South Carolina · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2007 to 2018
$14.2M
Epigenetic mechanisms in Transgenerational Effects of an Environmental PollutantR01ES030144 · NIEHS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2019 to 2023
$2.5M
Harnessing the Power of p53 with Panaxynol from American Ginseng to Suppress Colitis and Prevent Colon Cancer - admin suppR01CA246809 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HOFSETH, LORNE J, MURPHY, ELIZABETH ANGELA · 2020 to 2024
$2.2M
AhR ligands in epigenetic dysregulation of T cellsR01AI123947 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2017 to 2021
$1.8M
Immunopathological basis of PTSDR01MH094755 · NIMH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2011 to 2015
$1.7M
Cannabinoid-induced apoptosis in T cell regulationR01DA016545 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NAGARKATTI, PRAKASH S. · 2003 to 2007
$1.2M
NCCIH NIH HHS P01 AT003961NCI NIH HHS R01 CA246809NIDA NIH HHS R01 DA016545NIEHS NIH HHS R01 ES030144NIGMS NIH HHS P20 GM103641NIMH NIH HHS R01 MH094755
6 · The paper itself

Abstract

The purpose of our study is to explore the pharmacokinetic parameters of panaxynol (PA) and understand its potential and dosage used in pre-clinical animal models. For

Indexed as

BioavailabilityFalcarinolGinsengHalf-lifeMicePanaxynolPharmacokinetics

Identifiers

PMID32905447
PMCPMC7472592
OpenAlexW3028284749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.